TriSalus Life Sciences, Inc.

MedTech Acquisition Corp (Nasdaq: MTAC), a healthcare-focused blank-check company sponsored by MedTech Acquisition Holdings LLC, completed its business combination with TriSalus Life Sciences, Inc. in late 2022 following its initial public offering in 2021. TriSalus Life Sciences develops interventional oncology drug-delivery platforms designed to treat liver and pancreatic cancers, placing the transaction squarely within the medical device and therapeutic oncology sector. The December 2022 8-K filing reflects activity tied to the closing of that de-SPAC transaction, after which the combined company proceeded to trade under the ticker TLSI on Nasdaq. Sign up for full SPAC filing data and deal analytics at SpacDesk.